Ambrx®, Inc. is a clinical stage biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.
The company is developing ARX788 - a site-specific antibody drug conjugate for breast cancer and gastric cancer. In addition to its ADC collaborations with Astellas, Bristol-Myers Squibb and Zhejiang Medicine Co. Ltd, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Bristol-Myers Squibb, Eli Lilly and Hisun. Ambrx is developing a robust portfolio of product candidates that are optimized for efficacy and safety in oncology.
At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines. For additional information, visit www.ambrx.com.
Logo - http://photos.prnewswire.com/prnh/20151110/285915LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ambrxs-innovative-antibody-drug-conjugate-adc-us-ind-active-300314545.html
SOURCE Ambrx, Inc.